Literature DB >> 12651099

Notch signalling at the crossroads of T cell development and leukemogenesis.

Antonio F Campese1, Diana Bellavia, Alberto Gulino, Isabella Screpanti.   

Abstract

Members of the Notch family (e.g. Notch1 and Notch3) have been recently described to play a critical role in T cell development and their constitutive activation has been related to T cell leukaemia in both animal models and human disease. Nevertheless, whether they act as redundant molecules, by affecting the same molecular mechanisms, or play distinct roles in T cell differentiation and/or leukemogenesis is not clear. Altered Notch signalling impairs the developmentally-regulated interplay between pre-TCR signalling, NFkappaB and E2A activities, thus identifying the crucial role of Notch receptors at the cross-roads of disrupted lymphoid differentiation and neoplastic transformation. Copyright 2003 Elsevier Science Ltd.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12651099     DOI: 10.1016/s1084-9521(02)00184-2

Source DB:  PubMed          Journal:  Semin Cell Dev Biol        ISSN: 1084-9521            Impact factor:   7.727


  3 in total

1.  HTLV-1 propels thymic human T cell development in "human immune system" Rag2⁻/⁻ gamma c⁻/⁻ mice.

Authors:  Julien Villaudy; Mélanie Wencker; Nicolas Gadot; Nicolas A Gillet; Jean-Yves Scoazec; Louis Gazzolo; Markus G Manz; Charles R M Bangham; Madeleine Duc Dodon
Journal:  PLoS Pathog       Date:  2011-09-01       Impact factor: 6.823

Review 2.  Tumor microenvironment pathways: Cross regulation in breast cancer metastasis.

Authors:  Rama Rao Malla; P Kiran
Journal:  Genes Dis       Date:  2020-12-01

3.  Intrathymic Notch3 and CXCR4 combinatorial interplay facilitates T-cell leukemia propagation.

Authors:  Francesca Ferrandino; Giovanni Bernardini; Georgia Tsaouli; Paola Grazioli; Antonio Francesco Campese; Claudia Noce; Ambra Ciuffetta; Alessandra Vacca; Zein Mersini Besharat; Diana Bellavia; Isabella Screpanti; Maria Pia Felli
Journal:  Oncogene       Date:  2018-07-23       Impact factor: 9.867

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.